Bullish View On Netflix; Akebia Therapeutics Misses Q2 Expectations
- August 25th, 2023
- 494 views
Netflix, Inc. (Nasdaq: NFLX), a prominent streaming entertainment service, was upgraded from Hold to Buy by Loop Capital, accompanied by a revised price target increase from $425 to $500.
With $NFLX closing at $406.93 on Thursday, this updated price target suggests a potential upside of $93.07 or roughly 22.88%, based on the brokerage and advisory firm's analysis.
In other news, Akebia Therapeutics, Inc. (Nasdaq: AKBA), a pharmaceutical company, reported a second-quarter 2023 loss of $(0.06) per share, falling short of the consensus estimate loss of $(0.02). The company's quarterly sales totaled $56.38 million, slightly below analysts' projected revenue of $59.10 million for the period.
$AKBA was trading at $1.21 in pre-market, down $0.04 (-3.19%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025
Member Login